-  INCLUSION CRITERIA RECIPIENT:

          -  Ages 18-70 years inclusive

          -  Haploidentical donor available

          -  Any one of the following hematologic conditions meeting a standard indication for
             allogeneic stem cell transplant:

               -  Chronic myelogenous leukemia (CML): Subjects under the age of 21 in chronic phase
                  OR subjects ages 18-65 in chronic phase who have failed treatment with imatinib
                  or have intolerance to imatinib OR Subjects ages 18-65 in accelerated phase or
                  blast transformation. OR

               -  Acute lymphoblastic leukemia (ALL): any of these categories: Adult ALL including
                  standard risk. All second or subsequent remissions, primary induction failure,
                  partially responding or untreated relapse. OR

               -  Acute myelogenous leukemia (AML): AML in first remission - except AML with good
                  risk karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), c-kit unmutated AML t (8;
                  21). All AML in second or subsequent remission, primary induction failure and
                  resistant relapse. OR

               -  Myelodysplasticsyndromes(MDS): any of these categories - refractory anemia with
                  transfusion dependence, refractory anemia with ANC<500/ (Micro)L, refractory
                  anemia with excess of blasts, transformation to acute leukemia, chronic
                  myelomonocytic leukemia, atypical MDS/myeloproliferative syndromes. OR

               -  Myeloproliferative disorders including atypical (Ph-negative) chronic myeloid and
                  neutrophilic leukemias, progressing myelofibrosis, and polycythemia vera,
                  essential thrombocythemia either in transformation to acute leukemia or with
                  progressive transfusion requirements or pancytopenia. OR

               -  Non-Hodgkin s lymphoma including Mantle cell lymphoma relapsing or refractory to
                  standard of care treatments. OR

               -  Multiple myeloma, Waldenstroms macroglobulinemia, unresponsive or relapsed
                  following standard of care treatments. OR

               -  Hodgkin's Lymphoma relapsing following an autologous transplant. OR

               -  Other rare hematologic malignancies for which hematopoietic stem cell
                  transplantation has been performed and offers a durable remission or as the only
                  option with a potential for cure.

                    -  Chemotherapy-resistant multisystem Langerhans cell histiocytosis (MSLCH)
                       especially involving organs like the bone marrow, liver, spleen, and lungs

                    -  Aggressive systemic mastocytosis, and mast cell leukemia (MCL) in first CR
                       (CR1)

                    -  Hypereosinophilic syndrome who have failed imatinib therapy or
                       FIP1L1-PDGFRa-negative patients who develop end-organ dysfunction

                    -  Adult T-cell leukemia/lymphoma at first diagnosis

                    -  Refractory or disseminated nasal-type extranodal NK/T-lymphoma or aggressive
                       Natural killer cell leukemia/lymphoma

                    -  Mycosis fungoides and S(SqrRoot)(Copyright)zary syndrome after failure of
                       two or three initial therapies

                    -  Primary or relapsed refractory Angioimmunoblastic T-cell lymphoma at first
                       diagnosis

                    -  Hepatosplenic T-cell lymphoma (gamma/delta T-cell lymphoma) at first
                       diagnosis

                    -  T-cell prolymphocytic leukemia at first diagnosis

                    -  Subcutaneous panniculitic T-cell lymphoma at first diagnosis

                    -  Hematodermic neoplasm (blastic natural killer cell lymphoma or Blastic
                       plasmacytoid dendritic cell neoplasm) at first diagnosis

               -  Ability to comprehend the investigational nature of the study and provide
                  informed consent.

        EXCLUSION CRITERIA RECIPIENT (ANY OF THE FOLLOWING):

          -  HLA identical (6/6) related or (8/8 allele level matched) unrelated donor available
             and readily accessible at time of transplantation evaluation

          -  Major anticipated illness or organ failure incompatible with survival from transplant

          -  Severe psychiatric illness or mental deficiency sufficiently severe as to make
             compliance with the transplant treatment unlikely and making informed consent
             impossible.

          -  Positive pregnancy test for women of childbearing age

          -  Contraindication to receive IL-2 including:

               -  Hypersensitivity to IL-2

               -  Sustained ventricular tachycardia (>5 beats)

               -  Cardiac arrhythmias not controlled or unresponsive to management

               -  Chest pain with ECG changes, consistent with angina or myocardial infarction

               -  Cardiac tamponade

               -  Intubation for >72 hours

               -  Renal failure requiring dialysis >72 hours

               -  Coma or toxic psychosis lasting > 48 hours

               -  Repetitive or difficult to control seizures

               -  Active bowel ischemia or perforation

               -  Active GI bleeding requiring surgery

          -  DLCO adjusted for Hb and ventilation< 50% predicted

          -  Left ventricular ejection fraction < 40% (evaluated by ECHO) or < 30% (evaluated by
             MUGA)

          -  AST/SGOT > 5 times ULN

          -  Total bilirubin > 3 times ULN

          -  Estimated GFR <60ml/min (calculated by CKD-EPI, a formula routinely used in Clinical
             Research Center at National Institutes of Health. In case of borderline estimated GFR,
             CKD-EPI creatinine-cystatin C formula will be used for more accurate estimation)

          -  Prior allogeneic stem cell transplantation

        INCLUSION CRITERIA DONOR:

          -  Related donor who shares 1 haplotype with the recipient

          -  Age greater than or equal to 18 or less than or equal to 80 years old

          -  Ability to comprehend the investigational nature of the study and provide informed
             consent.

        EXCLUSION CRITERIA DONOR (ANY OF THE FOLLOWING):

          -  Unfit to receive G-CSF and undergo apheresis such as abnormal blood counts, history of
             stroke, uncontrolled hypertension

          -  Sickling hemaglobinopathy including HbSS, HbAS, HbSC

          -  Donors who are positive for HIV, active hepatitis B (HBV), hepatitis C (HCV) or human
             T-cell lymphotropic virus (HTLV-I/II)

          -  Severe psychiatric illness. Mental deficiency sufficiently severe as to make
             compliance with the BMT treatment unlikely and making informed consent impossible.